Johnson & Johnson (NYSE:JNJ) Shares Bought by Bell & Brown Wealth Advisors LLC

view original post

Bell & Brown Wealth Advisors LLC grew its holdings in shares of Johnson & Johnson (NYSE:JNJGet Rating) by 25.1% during the first quarter, Holdings Channel reports. The firm owned 2,901 shares of the company’s stock after acquiring an additional 582 shares during the quarter. Bell & Brown Wealth Advisors LLC’s holdings in Johnson & Johnson were worth $514,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds also recently modified their holdings of the business. Family CFO Inc acquired a new stake in shares of Johnson & Johnson in the 4th quarter worth about $26,000. Steward Financial Group LLC acquired a new stake in shares of Johnson & Johnson in the 4th quarter worth about $34,000. Joseph P. Lucia & Associates LLC acquired a new stake in shares of Johnson & Johnson in the 1st quarter worth about $38,000. Advocacy Wealth Management Services LLC increased its holdings in shares of Johnson & Johnson by 41.4% in the 1st quarter. Advocacy Wealth Management Services LLC now owns 229 shares of the company’s stock worth $41,000 after acquiring an additional 67 shares during the period. Finally, Gibson Wealth Advisors LLC acquired a new stake in shares of Johnson & Johnson in the 4th quarter worth about $49,000. 68.78% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of analysts recently weighed in on JNJ shares. Credit Suisse Group increased their price objective on shares of Johnson & Johnson from $200.00 to $205.00 and gave the stock an “outperform” rating in a report on Wednesday, April 20th. Daiwa Capital Markets assumed coverage on shares of Johnson & Johnson in a research note on Wednesday, June 22nd. They set an “outperform” rating on the stock. SVB Leerink lowered their target price on shares of Johnson & Johnson from $200.00 to $194.00 in a research note on Wednesday, July 20th. StockNews.com raised shares of Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research note on Tuesday, May 17th. Finally, The Goldman Sachs Group raised their target price on shares of Johnson & Johnson from $163.00 to $181.00 and gave the company a “neutral” rating in a research note on Tuesday, April 12th. Four research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, Johnson & Johnson has an average rating of “Moderate Buy” and an average target price of $189.89.

Johnson & Johnson Stock Performance

Shares of JNJ opened at $173.20 on Thursday. Johnson & Johnson has a one year low of $155.72 and a one year high of $186.69. The company has a 50-day moving average of $175.99 and a two-hundred day moving average of $174.36. The stock has a market cap of $455.76 billion, a price-to-earnings ratio of 25.21, a PEG ratio of 3.28 and a beta of 0.63. The company has a debt-to-equity ratio of 0.39, a current ratio of 1.39 and a quick ratio of 1.14.

Johnson & Johnson (NYSE:JNJGet Rating) last announced its earnings results on Tuesday, July 19th. The company reported $2.59 EPS for the quarter, topping the consensus estimate of $2.57 by $0.02. Johnson & Johnson had a net margin of 19.21% and a return on equity of 36.56%. The company had revenue of $24.02 billion during the quarter, compared to analysts’ expectations of $23.85 billion. During the same period last year, the company posted $2.48 earnings per share. The business’s revenue for the quarter was up 3.0% on a year-over-year basis. On average, equities research analysts expect that Johnson & Johnson will post 10.05 earnings per share for the current year.

Johnson & Johnson Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, September 6th. Stockholders of record on Tuesday, August 23rd will be given a $1.13 dividend. This represents a $4.52 dividend on an annualized basis and a dividend yield of 2.61%. The ex-dividend date of this dividend is Monday, August 22nd. Johnson & Johnson’s dividend payout ratio (DPR) is 65.79%.

Insider Transactions at Johnson & Johnson

In other news, CAO Robert J. Decker sold 8,462 shares of the stock in a transaction that occurred on Thursday, May 26th. The shares were sold at an average price of $180.00, for a total value of $1,523,160.00. Following the completion of the sale, the chief accounting officer now directly owns 15,473 shares of the company’s stock, valued at $2,785,140. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In other news, CAO Robert J. Decker sold 8,462 shares of the stock in a transaction that occurred on Thursday, May 26th. The shares were sold at an average price of $180.00, for a total value of $1,523,160.00. Following the completion of the sale, the chief accounting officer now directly owns 15,473 shares of the company’s stock, valued at $2,785,140. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Kathryn E. Wengel sold 40,000 shares of the stock in a transaction that occurred on Friday, June 10th. The stock was sold at an average price of $173.00, for a total transaction of $6,920,000.00. Following the completion of the sale, the executive vice president now directly owns 71,311 shares of the company’s stock, valued at $12,336,803. The disclosure for this sale can be found here. 0.35% of the stock is owned by insiders.

About Johnson & Johnson

(Get Rating)

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide. The company’s Consumer Health segment offers baby care products under the JOHNSON’S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR.

Read More

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJGet Rating).

Receive News & Ratings for Johnson & Johnson Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Johnson & Johnson and related companies with MarketBeat.com’s FREE daily email newsletter.

Related Posts